The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction
Marion Flechtner-Mors, 1 Ulrike Thoma, 2 Regina Wittmann, 2 Bernhard O Boehm, 2–4 Mona Mors, 1 Jürgen M Steinacker, 1 Uwe Schumann 1 1University Medical Center Ulm, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany; 2Department of Internal Med...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/40a089c1b79d4c979d2fc93d97097cd4 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| id |
oai:doaj.org-article:40a089c1b79d4c979d2fc93d97097cd4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:40a089c1b79d4c979d2fc93d97097cd42021-12-02T06:47:48ZThe Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction1178-7007https://doaj.org/article/40a089c1b79d4c979d2fc93d97097cd42020-02-01T00:00:00Zhttps://www.dovepress.com/the-effect-of-potato-protease-inhibitor-ii-on-gastrointestinal-hormone-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Marion Flechtner-Mors, 1 Ulrike Thoma, 2 Regina Wittmann, 2 Bernhard O Boehm, 2–4 Mona Mors, 1 Jürgen M Steinacker, 1 Uwe Schumann 1 1University Medical Center Ulm, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany; 2Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany; 3Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore; 4Imperial College London, London, UKCorrespondence: Marion Flechtner-MorsDepartment of Internal Medicine II, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Leimgrubenweg 14, Ulm 89075, GermanyTel + 49 731 50045330Fax + 49 731 50045333Email marion.flechtner-mors@uni-ulm.deContext: It is questioned whether the potato protein protease inhibitor II (PI2) reduces appetite and exerts effects on the satiety hormone cholecystokinin (CCK).Objective: To investigate PI2 impact on gastrointestinal hormones and appetite measures during weight reduction.Design: In a randomized, placebo-controlled trial over 20 weeks, fifty-two overweight/obese participants (BMI 25.2– 38.0 kg/m 2) received a protein-rich diet (30%) adjusted to 500 kcal below their individual daily needs. Subjects ingested a capsule containing either PI2 (150 mg) or placebo twice daily 1 hr before lunch and dinner. At week 0 and week 10 participants joined breakfast test meals to determine CCK, GLP-1, ghrelin, leptin, glucose and insulin concentrations in a time course experimental manner. Appetite sensations were measured on test meal days and in week 4, 9, 14 and 19 using visual analogue scales.Results: Weight loss at week 10 and 20 in the PI2 group was 4.3± 3.1 kg and 5.6± 4.1 kg, in the control group: 4.7± 4.0 kg and 6.8± 3.7 kg. A significant effect of PI2 on circulating CCK levels was observed at week 10. The other hormones were unaffected by PI2. At week 10, PI2 group subjects showed higher satiety and decreased desire to eat compared to placebo. During study duration, PI2 showed a significant impact on appetite ratings prior to lunch, one hour before dinner and just before dinner.Conclusion: PI2 increased circulating CCK plasma levels during the diet intervention. Likewise, PI2 modulated appetite sensation from week 4 to 20. The study demonstrated that the PI2 can modulate a key satiety signal.Keywords: dietary supplement, appetite, satiety modification, obesityFlechtner-Mors MThoma UWittmann RBoehm BOMors MSteinacker JMSchumann UDove Medical Pressarticledietary supplementappetitesatiety modificationobesitySpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 521-534 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
dietary supplement appetite satiety modification obesity Specialties of internal medicine RC581-951 |
| spellingShingle |
dietary supplement appetite satiety modification obesity Specialties of internal medicine RC581-951 Flechtner-Mors M Thoma U Wittmann R Boehm BO Mors M Steinacker JM Schumann U The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction |
| description |
Marion Flechtner-Mors, 1 Ulrike Thoma, 2 Regina Wittmann, 2 Bernhard O Boehm, 2–4 Mona Mors, 1 Jürgen M Steinacker, 1 Uwe Schumann 1 1University Medical Center Ulm, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Ulm, Germany; 2Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany; 3Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore; 4Imperial College London, London, UKCorrespondence: Marion Flechtner-MorsDepartment of Internal Medicine II, Division of Sports and Rehabilitation Medicine, University Hospital Ulm, Leimgrubenweg 14, Ulm 89075, GermanyTel + 49 731 50045330Fax + 49 731 50045333Email marion.flechtner-mors@uni-ulm.deContext: It is questioned whether the potato protein protease inhibitor II (PI2) reduces appetite and exerts effects on the satiety hormone cholecystokinin (CCK).Objective: To investigate PI2 impact on gastrointestinal hormones and appetite measures during weight reduction.Design: In a randomized, placebo-controlled trial over 20 weeks, fifty-two overweight/obese participants (BMI 25.2– 38.0 kg/m 2) received a protein-rich diet (30%) adjusted to 500 kcal below their individual daily needs. Subjects ingested a capsule containing either PI2 (150 mg) or placebo twice daily 1 hr before lunch and dinner. At week 0 and week 10 participants joined breakfast test meals to determine CCK, GLP-1, ghrelin, leptin, glucose and insulin concentrations in a time course experimental manner. Appetite sensations were measured on test meal days and in week 4, 9, 14 and 19 using visual analogue scales.Results: Weight loss at week 10 and 20 in the PI2 group was 4.3± 3.1 kg and 5.6± 4.1 kg, in the control group: 4.7± 4.0 kg and 6.8± 3.7 kg. A significant effect of PI2 on circulating CCK levels was observed at week 10. The other hormones were unaffected by PI2. At week 10, PI2 group subjects showed higher satiety and decreased desire to eat compared to placebo. During study duration, PI2 showed a significant impact on appetite ratings prior to lunch, one hour before dinner and just before dinner.Conclusion: PI2 increased circulating CCK plasma levels during the diet intervention. Likewise, PI2 modulated appetite sensation from week 4 to 20. The study demonstrated that the PI2 can modulate a key satiety signal.Keywords: dietary supplement, appetite, satiety modification, obesity |
| format |
article |
| author |
Flechtner-Mors M Thoma U Wittmann R Boehm BO Mors M Steinacker JM Schumann U |
| author_facet |
Flechtner-Mors M Thoma U Wittmann R Boehm BO Mors M Steinacker JM Schumann U |
| author_sort |
Flechtner-Mors M |
| title |
The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction |
| title_short |
The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction |
| title_full |
The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction |
| title_fullStr |
The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction |
| title_full_unstemmed |
The Effect of Potato Protease Inhibitor II on Gastrointestinal Hormones and Satiety in Humans During Weight Reduction |
| title_sort |
effect of potato protease inhibitor ii on gastrointestinal hormones and satiety in humans during weight reduction |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/40a089c1b79d4c979d2fc93d97097cd4 |
| work_keys_str_mv |
AT flechtnermorsm theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT thomau theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT wittmannr theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT boehmbo theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT morsm theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT steinackerjm theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT schumannu theeffectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT flechtnermorsm effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT thomau effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT wittmannr effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT boehmbo effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT morsm effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT steinackerjm effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction AT schumannu effectofpotatoproteaseinhibitoriiongastrointestinalhormonesandsatietyinhumansduringweightreduction |
| _version_ |
1718399749595332608 |